Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
Presently, no tetraspecific antibodies have entered into the commercial global market, thereby, representing an opportunity for pharma companies to advance the realm of tetraspecific antibodies. As per KuicK Research data, it is obvious that the comprehensive tetraspecific antibodies domain will modernize the treatment portrait for cancer ailments in next 5 to 7 years due to the fact that the up-to-date emphasis of pharma and biotech companies oscillates in the sphere of targeted therapies. The example of bispecific antibodies serves as the establishment for this. More than 100 contenders entered into the clinical conduit when the first bispecific antibody, Blincyto, triumph the market. Similarly, the realm of tetraspecific antibodies, for that reason, is estimated to follow an analogous triumph trajectory given that they are fundamentally an up gradation over bispecific and trispecific antibodies.
The commercial market of tetraspecific antibody is witnessing boom in the recent years on the account of several market dynamics. Aspects such as rise in preclinical and clinical trials, involvement of stakeholders, and technological advancement in conjugation with increase in healthcare expenditure are fueling the market growth of immunotherapies. Albeit, immune checkpoint blockers or drugs such as pembrolizumab (Keytruda), ipilimumab (Yervoy), etc. have frolicked a significant role in the treatment of wide array of cancer ailments; however, their ability to show effectiveness in subsets of patients as well as development of drug resistance is one of the Achilles heels, creating a significant unfulfilled gap. This drives the global shift of healthcare professionals from using monospecific therapies on the roadmap to tetraspecific antibodies domain.
Alongside, the upsurge in preclinical, translational coupled with other clinical trials is another characteristics which is influencing the global tetraspecific antibody commercial market. For instance, Baili-Bio (Chengdu) Pharmaceutical has inaugurated an open, multicenter, phase I/ II clinical trial with the purpose to evaluate the safety, tolerability, pharmacokinetics/ pharmacodynamics as well as antitumor activity of GNC-035, an octavalent, tetra specific T cell engager targeting ROR1, CD3, PD-L1, and 4-1BB, in patients suffering with relapsed or refractory Non-Hodgkin’s lymphoma and other hematological malignancies. The clinical trial has an estimated enrollment of 40 participants that was initiated in November 2023 and is expected to be complete by November 2025.
As well as, the presences of pharma companies, like Sichuan Biokin Pharmaceuticals along with its subsidiaries, such as Systimmune, Sichuan Baili Pharmaceutical Co, ModeX Therapeutics, an OPKO Health Company, and Molecular Partners accompanied with universities and hospitals, like Ruijin Hospital, is another prime mover for the market expansion of tetraspecific antibody arena.
To conclude, China is frontrunner in the domain of global tetraspecific antibody market; nevertheless, US is also engaged on its technology and mounting collaboration through global companies to progress tetraspecific antibodies. Furthermore, the development of combinations of tetraspecific antibodies is also pragmatic in the recent year, thus, representing gigantic opportunism in the years to come.
Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024 Report Highlights:
- First Tetraspecific Antibody Expected Approval By 2029
- China Dominating Global Tetraspecific Development Landscape
- Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
- Tetraspecific Antibody Clinical Development Trend Analysis by Region: China, Europe & USA
- Tetraspecific Development Proprietary Technologies By Company
- Combination Stratagems for Tetraspecific Antibodies
Presently, no tetraspecific antibodies have entered into the commercial global market, thereby, representing an opportunity for pharma companies to advance the realm of tetraspecific antibodies. As per KuicK Research data, it is obvious that the comprehensive tetraspecific antibodies domain will modernize the treatment portrait for cancer ailments in next 5 to 7 years due to the fact that the up-to-date emphasis of pharma and biotech companies oscillates in the sphere of targeted therapies. The example of bispecific antibodies serves as the establishment for this. More than 100 contenders entered into the clinical conduit when the first bispecific antibody, Blincyto, triumph the market. Similarly, the realm of tetraspecific antibodies, for that reason, is estimated to follow an analogous triumph trajectory given that they are fundamentally an up gradation over bispecific and trispecific antibodies.
The commercial market of tetraspecific antibody is witnessing boom in the recent years on the account of several market dynamics. Aspects such as rise in preclinical and clinical trials, involvement of stakeholders, and technological advancement in conjugation with increase in healthcare expenditure are fueling the market growth of immunotherapies. Albeit, immune checkpoint blockers or drugs such as pembrolizumab (Keytruda), ipilimumab (Yervoy), etc. have frolicked a significant role in the treatment of wide array of cancer ailments; however, their ability to show effectiveness in subsets of patients as well as development of drug resistance is one of the Achilles heels, creating a significant unfulfilled gap. This drives the global shift of healthcare professionals from using monospecific therapies on the roadmap to tetraspecific antibodies domain.
Alongside, the upsurge in preclinical, translational coupled with other clinical trials is another characteristics which is influencing the global tetraspecific antibody commercial market. For instance, Baili-Bio (Chengdu) Pharmaceutical has inaugurated an open, multicenter, phase I/ II clinical trial with the purpose to evaluate the safety, tolerability, pharmacokinetics/ pharmacodynamics as well as antitumor activity of GNC-035, an octavalent, tetra specific T cell engager targeting ROR1, CD3, PD-L1, and 4-1BB, in patients suffering with relapsed or refractory Non-Hodgkin’s lymphoma and other hematological malignancies. The clinical trial has an estimated enrollment of 40 participants that was initiated in November 2023 and is expected to be complete by November 2025.
As well as, the presences of pharma companies, like Sichuan Biokin Pharmaceuticals along with its subsidiaries, such as Systimmune, Sichuan Baili Pharmaceutical Co, ModeX Therapeutics, an OPKO Health Company, and Molecular Partners accompanied with universities and hospitals, like Ruijin Hospital, is another prime mover for the market expansion of tetraspecific antibody arena.
To conclude, China is frontrunner in the domain of global tetraspecific antibody market; nevertheless, US is also engaged on its technology and mounting collaboration through global companies to progress tetraspecific antibodies. Furthermore, the development of combinations of tetraspecific antibodies is also pragmatic in the recent year, thus, representing gigantic opportunism in the years to come.
1. INTRODUCTION TO TETRASPECIFIC ANTIBODIES
1.1 Clinical Overview
1.2 History & Development
2. TETRASPECIFIC ANTIBODIES MECHANISM OF ACTION
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer
3. TETRASPECIFIC ANTIBODIES CLINICAL TRIALS OVERVIEW
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication
4. TETRASPECIFIC ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II
5. CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK
5.1 Current Scenario
5.2 Future Market Commercialization Outlook
6. TETRASPECIFIC ANTIBODY CLINICAL DEVELOPMENT TREND ANALYSIS BY REGION
6.1 China
6.2 Europe
6.3 US
7. TETRASPECIFIC ANTIBODIES PROPRIETARY TECHNOLOGIES BY COMPANY
7.1 Available Proprietary Platforms
7.2 Potential Proprietary Platforms
8. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPLICATION IN CANCER
8.1 Solid Tumors
8.2 Hematological Disorders
9. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPROACHES
9.1 Tetraspecific Antibodies As Monotherapy
9.2 Tetraspecific Antibodies As Combinational Therapy
9.3 Tetraspecific Antibodies As Targeted Approach
10. COMBINATION STRATAGEMS FOR TETRASPECIFIC ANTIBODIES
11. COMPETITIVE LANDSCAPE
11.1 Innate Pharma
11.2 ModeX Therapeutics (OPKO Health) 11.3
11.3 Molecular Partners
11.4 OPKO Health
11.454 Ruijin Hospital
11.6 Sichuan Baili Pharmaceutical
11.7 SystImmune
Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity
Figure 3-1: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024
Figure 3-2: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024
Figure 3-3: Global – Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024
Figure 3-4: Global – Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024
Figure 6-1: Sichuan Biokin Pharmaceutical – Clinical Pipeline
Figure 6-2: GNC-035 Phase I Study (NCT05160545) – Initiation & Completion Year
Figure 6-3: IPH6501 Phase I/II Study (NCT06088654) – Initiation & Completion Year
Figure 6-4: ModeX Therapeutics, an OPKO Health Company Pipeline
Figure 7-1: DARPin Platform - Molecular Partners
Figure 7-2: ANKET® Platform - Innate Pharma
Figure 7-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 7-4: STEALTH – ModeX Therapeutics
Figure 7-5: MSTAR – ModeX Therapeutics
Figure 7-6: Features of MSTAR
Figure 7-7: MATCH – Numab
Figure 7-8: Features of BiXAb
Figure 7-9: Zyngenia Technology Approach
Figure 8-1: GNC-039 Phase I Study (NCT04794972) – Initiation & Completion Year
Figure 8-2: MDX2001 Phase I/II Study (NCT06239194) – Initiation & Completion Year
Figure 8-3: GNC-038 Phase I/II Study (NCT05627856) – Initiation & Completion Year
Figure 8-4: GNC-038 Phase I/II Study (NCT05485753) – Initiation & Completion Years
Figure 8-5: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-6: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-7: Molecular Partners – MP0533
Figure 8-8: MP0533 Phase I/II Study (NCT05673057) – Initiation & Completion Year
Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development
Figure 10-1: Tetraspecific Antibody Combinations
Table 6-1: China – Ongoing Tetraspecific Antibody Clinical Trials
Table 9-2: GNC-038– Ongoing Clinical Trial for Hematological Cancers
Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies
1.1 Clinical Overview
1.2 History & Development
2. TETRASPECIFIC ANTIBODIES MECHANISM OF ACTION
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells & Target Cells Closer
3. TETRASPECIFIC ANTIBODIES CLINICAL TRIALS OVERVIEW
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication
4. TETRASPECIFIC ANTIBODIES CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE
4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II
5. CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK
5.1 Current Scenario
5.2 Future Market Commercialization Outlook
6. TETRASPECIFIC ANTIBODY CLINICAL DEVELOPMENT TREND ANALYSIS BY REGION
6.1 China
6.2 Europe
6.3 US
7. TETRASPECIFIC ANTIBODIES PROPRIETARY TECHNOLOGIES BY COMPANY
7.1 Available Proprietary Platforms
7.2 Potential Proprietary Platforms
8. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPLICATION IN CANCER
8.1 Solid Tumors
8.2 Hematological Disorders
9. TETRASPECIFIC ANTIBODIES THERAPEUTIC APPROACHES
9.1 Tetraspecific Antibodies As Monotherapy
9.2 Tetraspecific Antibodies As Combinational Therapy
9.3 Tetraspecific Antibodies As Targeted Approach
10. COMBINATION STRATAGEMS FOR TETRASPECIFIC ANTIBODIES
11. COMPETITIVE LANDSCAPE
11.1 Innate Pharma
11.2 ModeX Therapeutics (OPKO Health) 11.3
11.3 Molecular Partners
11.4 OPKO Health
11.454 Ruijin Hospital
11.6 Sichuan Baili Pharmaceutical
11.7 SystImmune
Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells & NK Cells In Close Proximity
Figure 3-1: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024
Figure 3-2: Global – Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024
Figure 3-3: Global – Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024
Figure 3-4: Global – Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024
Figure 6-1: Sichuan Biokin Pharmaceutical – Clinical Pipeline
Figure 6-2: GNC-035 Phase I Study (NCT05160545) – Initiation & Completion Year
Figure 6-3: IPH6501 Phase I/II Study (NCT06088654) – Initiation & Completion Year
Figure 6-4: ModeX Therapeutics, an OPKO Health Company Pipeline
Figure 7-1: DARPin Platform - Molecular Partners
Figure 7-2: ANKET® Platform - Innate Pharma
Figure 7-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 7-4: STEALTH – ModeX Therapeutics
Figure 7-5: MSTAR – ModeX Therapeutics
Figure 7-6: Features of MSTAR
Figure 7-7: MATCH – Numab
Figure 7-8: Features of BiXAb
Figure 7-9: Zyngenia Technology Approach
Figure 8-1: GNC-039 Phase I Study (NCT04794972) – Initiation & Completion Year
Figure 8-2: MDX2001 Phase I/II Study (NCT06239194) – Initiation & Completion Year
Figure 8-3: GNC-038 Phase I/II Study (NCT05627856) – Initiation & Completion Year
Figure 8-4: GNC-038 Phase I/II Study (NCT05485753) – Initiation & Completion Years
Figure 8-5: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-6: GNC-035 Phase I/II Study (NCT06066203) – Initiation & Completion Years
Figure 8-7: Molecular Partners – MP0533
Figure 8-8: MP0533 Phase I/II Study (NCT05673057) – Initiation & Completion Year
Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research & Early Development
Figure 10-1: Tetraspecific Antibody Combinations
Table 6-1: China – Ongoing Tetraspecific Antibody Clinical Trials
Table 9-2: GNC-038– Ongoing Clinical Trial for Hematological Cancers
Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies
